P450-mediated
bioactivation of azoxymethane (AOM), a colon carcinogen,
leads to the formation of DNA adducts, of which O6-methylguanine (O6-mG) is the most mutagenic
and contributes to colon tumorigenesis. To determine whether P450
enzymes of the liver and intestine both contribute to AOM bioactivation in vivo, we compared tissue levels of AOM-induced DNA adducts,
microsomal AOM metabolic activities, and incidences of colonic aberrant
crypt foci (ACF) among wild-type (WT), liver-specific P450 reductase
(Cpr)-null (LCN), and intestinal epithelium-specific Cpr-null (IECN)
mice. At 6 h following AOM treatment (at 14 mg/kg, s.c.), O6-mG and N7-mG levels were highest in the liver, followed
by the colon, and then small intestine in WT mice. As expected, hepatic
adduct levels were significantly lower (by >60%) in LCN mice but
unchanged
in IECN mice, whereas small-intestinal adduct levels were unchanged
or increased in LCN mice but lower (by >50%) in IECN mice compared
to that in WT mice. However, colonic adduct levels were unchanged
in IECN mice compared to that in WT mice and increased in LCN mice
(by 1.5–2.9-fold). The tissue-specific impact of the CPR loss
in IECN and LCN mice on microsomal AOM metabolic activity was confirmed
by rates of formation of formaldehyde and N7-mG in vitro. Furthermore, the incidence of ACF, a lesion preceding
colon cancer, was similar in the three mouse strains. Thus, AOM-induced
colonic DNA damage and ACF formation is not solely dependent on either
hepatic or intestinal microsomal P450 enzymes. P450 enzymes in both
the liver and intestine likely contribute to AOM-induced colon carcinogenesis.